What's breaking now, across thousands of outlets.
Futures on the Dow were significantly worse than the S&P 500 because of a cardiovascular drug’s late-stage setback.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Guy Johnson, Tom Mackenzie and Adam Linton break down today's key themes for analysts and investors on "Bloomberg: The Opening Trade." (Source: Bloomberg)
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
The specialist health economics modeling and analytics business joins Initiate's market access and HEOR platform. The post QPE’s Initiate completes add-on acquisition of Dark Peak Analytics appeared…
More than 60% of cryptocurrency platforms that lost money due to cyberattacks had undergone independent security audits, CoinGecko said.
